獼猴是人類的近親，也是在研究中最廣泛使用的非人靈長類模式動物,。雖然獼猴在生物學和醫(yī)學方面的應用已經(jīng)有很長的時間,，但人們對獼猴基因組序列多態(tài)性的了解卻非常有限,。
中國科學院昆明動物研究所宿兵實驗室（博士研究生張雁峰等）和華大基因合作,，采用二代測序的方法對中國獼猴進行了全基因組序列分析。測序深度為獼猴基因組11.56倍的覆蓋率,。通過和國外已測的印度獼猴基因組序列的比較,，他們共發(fā)現(xiàn)了550萬個單核苷酸序列多態(tài)性位點（SNP），其中294萬個SNP是中國獼猴基因組中的雜合多態(tài)性,，256萬個SNP是中國獼猴和印度獼猴間的差異位點,。同時，他們還發(fā)現(xiàn)了12萬多個的基因組結(jié)構(gòu)變異（Structural variation, SV）,。
這項工作是首次對獼猴全基因組序列多態(tài)性的解析,，所報道的海量序列多態(tài)數(shù)據(jù)將為以獼猴為對象的生物學和臨床前醫(yī)學研究提供具有重要價值的數(shù)據(jù)庫。相關研究結(jié)果發(fā)表于基因組學的知名刊物《基因組生物學》（Genome Biology）,。（生物谷Bioon.com）
生物谷推薦原文出處：
Genome Biology doi:10.1016/j.addr.2011.05.005
Viral delivery for gene therapy against cell movement in cancer
Te-Lang Wu and Dongming Zhou
Viral delivery for cancer gene therapy is a promising approach, where traditional radiotherapy or chemotherapy to limit proliferation and movement of cancer cells has met resistance. Based on the new understanding of the biology of the viral vectors, therapeutic viral vectors for cancer gene therapy have been improved for greater safety and efficacy as well as transitioned from being non-replicating to replication-competent. Traditional oncolytic vectors have focused on eliminating tumor growth, while novel vectors simultaneously target epithelial-to-mesenchymal transition (EMT) in cancer cells, which could further prevent and reverse the aggressive tumor progression. In this review, we highlight the illustrative examples of cancer gene therapy in clinical trials as well as preclinical data and include proposals on methods to further enhance the safety and efficacy of oncolytic viral vectors in cancer gene therapy.
